GALNT9: Polypeptide N-Acetylgalactosaminyltransferase 9

A member of the UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase family involved in mucin-type O-glycosylation.

Gene Information Card

Symbol GALNT9
Full Name Polypeptide N-acetylgalactosaminyltransferase 9
Gene Type Protein coding
Chromosomal Location 12q24.33
NCBI Gene ID 50614 ncbi.nlm.nih.gov/gene/50614
Ensembl ID ENSG00000182870
UniProt ID Q6L8Q7
OMIM ID 608251
HGNC ID 4127
Aliases GALNAC-T9, GalNAc-T9, pp-GalNAc-T9

Description

GALNT9 encodes a member of the UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T) family. These enzymes catalyze the initial step of mucin-type O-linked glycosylation, transferring N-acetylgalactosamine (GalNAc) to serine or threonine residues on target proteins. GALNT9 is specifically expressed in the brain and testis and is involved in the regulation of protein function through O-glycosylation.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Cancer (various types) Altered O-glycosylation patterns; GALNT9 expression changes may affect tumor progression and metastasis. COSMIC database reports mutations in multiple cancer types; expression changes observed in breast, colorectal, and lung cancers.
Intellectual disability Potential role in neurodevelopment; rare variants reported in patients with developmental delay. ClinVar entries for missense variants of uncertain significance.

Expression Profile

Tissue Expression
Tissue nTPM level
Brain 12.5 Medium
Testis 8.3 Medium
Thyroid 3.1 Low
Adrenal gland 2.0 Low
Liver 0.5 Not detected
Cell Line Expression
Cell Line nTPM Notes
SH-SY5Y (neuroblastoma) 15.2 High expression; neuronal origin
U-87 MG (glioblastoma) 10.8 Moderate expression
MCF7 (breast cancer) 2.1 Low expression
HEK293 (embryonic kidney) 1.3 Low expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.1015C>T (p.Arg339Cys) Missense 0.01% (gnomAD) Uncertain significance; may affect catalytic activity
c.1342G>A (p.Gly448Ser) Missense 0.005% (gnomAD) Uncertain significance; reported in ClinVar
c.1720_1721insA (p.Thr574AsnfsTer5) Frameshift Rare Loss of function; truncation of C-terminal domain
Mutation functional classification

Loss of Function (LOF)

Frameshift and nonsense mutations predicted to truncate the protein, likely abolishing enzymatic activity.

Gain of Function (GOF)

No evidence for gain-of-function mutations in GALNT9.

Dominant Negative (DN)

No known dominant-negative effects reported.

Pathways

• Mucin-type O-glycan biosynthesis (Reactome: R-HSA-913709)
• O-linked glycosylation of mucins (KEGG: hsa00512)

Protein Summary

GALNT9 is a type II transmembrane protein localized to the Golgi apparatus. It catalyzes the transfer of GalNAc to serine/threonine residues, initiating mucin-type O-glycosylation. The protein contains a catalytic domain and a lectin domain that may facilitate substrate recognition. It is predominantly expressed in brain and testis, suggesting specialized roles in neuronal and reproductive tissues.

Related Products

Product name Cat.No. Species Gene ID
GALNT9 Knockout HEK293 Cell Line EDJ-KQ10782 Human 50614 Details Get a Quote
GALNT9 Knockout HeLa Cell Line EDJ-KQ56172 Human 50614 Details Get a Quote
GALNT9 Knockout A-549 Cell Line EDJ-KQ64662 Human 50614 Details Get a Quote
GALNT9 Knockout HCT 116 Cell Line EDJ-KQ73111 Human 50614 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: